Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Perspective

Effects of Prokinetics on the Digestive Tract

Author(s): Paolo Usai-Satta*, Mariantonia Lai , Francesco Oppia and Francesco Cabras

Volume 17, Issue 3, 2022

Published on: 05 August, 2021

Page: [161 - 165] Pages: 5

DOI: 10.2174/2772432816666210805125813

Abstract

Background: Functional gastrointestinal disorders account for at least a third of visits to gastroenterology clinics. Despite pathophysiological complexity, impaired gut motility may be frequently present in these disorders.

Introduction: Prokinetics are a class of drugs that promote gastrointestinal motility, accelerate transit, and potentially improve digestive symptoms. Several prokinetic agents with a great variety of mechanisms of action are available.

Aim: The purpose of this paper is to update our current knowledge about the efficacy and safety of prokinetics.

Methods: A literature search on efficacy and safety of prokinetics was carried out using the online databases of Pubmed, Medline, and Cochrane.

Results: Based on the action of different receptors, prokinetics mainly comprise dopamine antagonists, 5HT4 agonists, motilin agonists, ghrelin agonists, and cholinergic agonists. Prokinetics have the potential to improve motility function in all segments of the digestive tract, from the esophagus to the colon. In particular, drug international agencies have approved antidopaminergic metoclopramide for the treatment of gastroparesis and serotoninergic prucalopride for chronic constipation not responsive to traditional laxatives. Arrhythmias by QT prolongation and galactorrhea by prolactin stimulation are the more frequent side effects related to prokinetics use.

Conclusion: Old and new prokinetics are effective in ameliorating digestive motility disorders and related symptoms and are widely prescribed. Special attention should be paid to the potential adverse events of these agents.

Keywords: Prokinetics, gastric emptying, small bowel motility, constipation, safety, functional gastrointestinal disorders.

Next »
Graphical Abstract
[1]
Black CJ, Drossman DA, Talley NJ, Ruddy J, Ford AC. Functional gastrointestinal disorders: Advances in understanding and management. Lancet 2020; 396(10263): 1664-74.
[http://dx.doi.org/10.1016/S0140-6736(20)32115-2] [PMID: 33049221]
[2]
Camilleri M, Bueno L, Andresen V, De Ponti F, Choi MG, Lembo A. Pharmacological, pharmacokinetic, and pharmacogenomic aspects of functional gastrointestinal disorders. Gastroenterology 2016; S0016-5085(16): 00220-1.
[3]
Quigley EMM. Prokinetics in the management of functional gastrointestinal disorders. Curr Gastroenterol Rep 2017; 19(10): 53.
[http://dx.doi.org/10.1007/s11894-017-0593-6] [PMID: 28887755]
[4]
Deane AM, Chapman MJ, Abdelhamid YA. Any news from the prokinetic front? Curr Opin Crit Care 2019; 25(4): 349-55.
[http://dx.doi.org/10.1097/MCC.0000000000000634] [PMID: 31247631]
[5]
Jin M, Son M. DA-9701 (Motilitone): A multi-targeting botanical drug for the treatment of functional dyspepsia. Int J Mol Sci 2018; 19(12): 4035.
[http://dx.doi.org/10.3390/ijms19124035] [PMID: 30551633]
[6]
Vandenberghe A, Schol J, Van den Houte K, Masuy I, Carbone F, Tack J. Current and emerging therapeutic options for the management of functional dyspepsia. Expert Opin Pharmacother 2020; 21(3): 365-76.
[http://dx.doi.org/10.1080/14656566.2019.1707805] [PMID: 31899982]
[7]
Gholipour BA, Alipour A, Firouzian A, Moarab L, Emami Zeydi A. A double-blind randomized clinical trial comparing the effect of neostigmine and metoclopramide on gastric residual volume of mechanically ventilated ICU patients. Acta Inform Med 2016; 24(6): 385-9.
[http://dx.doi.org/10.5455/aim.2016.24.385-389] [PMID: 28077899]
[8]
Gyawali CP, Sifrim D, Carlson DA, et al. Ineffective esophageal motility: Concepts, future directions, and conclusions from the Stanford 2018 symposium. Neurogastroenterol Motil 2019; 31(9): e13584.
[http://dx.doi.org/10.1111/nmo.13584] [PMID: 30974032]
[9]
Xi L, Zhu J, Zhang H, Muktiali M, Li Y, Wu A. The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: A meta-analysis. Esophagus 2021; 18(1): 144-51.
[http://dx.doi.org/10.1007/s10388-020-00753-6] [PMID: 32519226]
[10]
Usai-Satta P, Bellini M, Morelli O, Geri F, Lai M, Bassotti G. Gastroparesis: New insights into an old disease. World J Gastroenterol 2020; 26(19): 2333-48.
[http://dx.doi.org/10.3748/wjg.v26.i19.2333] [PMID: 32476797]
[11]
Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol 2008; 8(6): 690-6.
[http://dx.doi.org/10.1016/j.coph.2008.09.009] [PMID: 18940266]
[12]
Pittayanon R, Yuan Y, Bollegala NP, et al. Prokinetics for functional dyspepsia: A systematic review and meta-analysis of randomized control trials. Am J Gastroenterol 2019; 114(2): 233-43.
[http://dx.doi.org/10.1038/s41395-018-0258-6] [PMID: 30337705]
[13]
Pittayanon R, Yuan Y, Bollegala NP, Khanna R, Leontiadis GI, Moayyedi P. Prokinetics for functional dyspepsia. Cochrane Database Syst Rev 2018; 10(10): CD009431.
[PMID: 30335201]
[14]
Emmanuel AV, Kamm MA, Roy AJ, Kerstens R, Vandeplassche L. Randomised clinical trial: The efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction-a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther 2012; 35(1): 48-55.
[http://dx.doi.org/10.1111/j.1365-2036.2011.04907.x] [PMID: 22061077]
[15]
Gonzalez Z, McCallum R. Small bowel dysmotility, pseudoobstruction, and functional correlation with histopathology: Lessons learned. Curr Gastroenterol Rep 2020; 22(3): 14.
[http://dx.doi.org/10.1007/s11894-020-0748-8] [PMID: 32078071]
[16]
Zatorski H, Mosinska P, Storr M, Fichna J. Relamorelin and other ghrelin receptor agonists - future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease. J Physiol Pharmacol 2017; 68(6): 797-805.
[PMID: 29550791]
[17]
Camilleri M, Piessevaux H, Yiannakou Y, et al. Efficacy and safety of prucalopride in chronic constipation: An integrated analysis of six randomized, controlled clinical trials. Dig Dis Sci 2016; 61(8): 2357-72.
[http://dx.doi.org/10.1007/s10620-016-4147-9] [PMID: 27056037]
[18]
Bassotti G, Usai Satta P, Bellini M. Prucalopride for the treatment of constipation: A view from 2015 and beyond. Expert Rev Gastroenterol Hepatol 2019; 13(3): 257-62.
[http://dx.doi.org/10.1080/17474124.2019.1568238] [PMID: 30791758]
[19]
Usai-Satta P, Bellini M, Lai M, Oppia F, Cabras F. Therapeutic approach for irritable bowel syndrome: Old and new strategies. Curr Clin Pharmacol 2018; 13(3): 164-72.
[http://dx.doi.org/10.2174/1574884713666180807143606] [PMID: 30084333]
[20]
Nelson AD, Camilleri M, Chirapongsathorn S, et al. Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: A systematic review and network meta-analysis. Gut 2017; 66(9): 1611-22.
[http://dx.doi.org/10.1136/gutjnl-2016-311835] [PMID: 27287486]
[21]
Acosta A, Camilleri M, Busciglio I, Boldingh A, Nelson AD, Burton D. Short-term effects of relamorelin on descending colon motility in chronic constipation: A randomized, controlled trial. Dig Dis Sci 2016; 61(3): 852-60.
[http://dx.doi.org/10.1007/s10620-015-3876-5] [PMID: 26467700]
[22]
Serra J, Pohl D, Azpiroz F, et al. European society of neurogastroenterology and motility guidelines on functional constipation in adults. Neurogastroenterol Motil 2020; 32(2): e13762.
[http://dx.doi.org/10.1111/nmo.13762] [PMID: 31756783]
[23]
Giudicessi JR, Ackerman MJ, Camilleri M. Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias. Neurogastroenterol Motil 2018; 30(6): e13302.
[http://dx.doi.org/10.1111/nmo.13302] [PMID: 29441683]

© 2023 Bentham Science Publishers | Privacy Policy